Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to […]
The post Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com